Linaclotide 72 micrograms
ApprovedSmall molecule
Linaclotide 72 micrograms is one of 24 small molecule programs targeting Chronic constipation. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in Chronic Constipation
#DrugCompanyPhaseTrials
1Resotran
TakedaApproved
Golytely
BayerApproved
Linzess
AbbViePhase 3
Zelnorm
AAlfasigma S.p.A.
Phase 3
Chronulac
SSolvay Pharmaceuticals
Phase 3
Lactobacillus Reuteri
TTulane University School of Medicine
Phase 3
Amitiza
SSucampo Pharma Americas, LLC
Phase 2
Elobixibat
FerringApproved
E. Coli Nissle 1917
KKangbuk Samsung Hospital
Approved
Macrogol 4000
IIstituto Clinico Humanitas
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Linaclotide 72 micrograms. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMd Mehedi Shahriar